Hair Problems
Methodology & AI Transparency ⓘ
Hair Problems Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: The average person has 5 million hairs.
- 2 Real-world patient consensus: Federal ICD-10-CM code L60.4 categorizes Hair Problems under Hair Loss, Alopecia & Scalp Conditions.
- 3 Typical cash cost range: Differential triage of Hair Problems (L60.4) utilizes minoxidil growth-phase extension [Hair Problems L60.4].
- 4 Top reported side effects / signs: Objective lab/clinical target for Hair Problems: Serum Ferritin [Hair Problems L60.4] (70 – 150 ng/mL (L60.4)) and TSH & Free in Hair Problems (L60.4: T4).
Ask our AI Specialists anything about Hair Problems
What Is Hair Problems?
The average person has 5 million hairs. Hair grows all over your body except on your lips, palms, and the soles of your feet. It takes about a month for healthy hair to grow half an inch. Most hairs grow for up to six years and then fall out. New hairs grow in their place. Hair helps keep you warm. It also protects your eyes, ears and nose from small particles in the air. Common problem with the hair and scalp include hair loss , infections, and flaking .
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Hair Problems (ICD-10 L60.4) is driven by or stress/nutrient-triggered telogen in Hair Problems (L60.4: shift); Cross-referenced with NIH MeSH (Hair Diseases, Dandruff), specialists in Hair Loss, Alopecia & Scalp Conditions monitor TSH & Free in Hair Problems (L60.4: T4) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Hair Problems (L60.4): gradual widening of in Hair Problems (L60.4: the central scalp)
- • Secondary Hair Problems clinical sign: excess telogen hair in Hair Problems (L60.4: shedding)
- • Symptom flares in Hair Problems correlating with Serum Ferritin [Hair Problems L60.4] deviation outside 70 – 150 ng/mL (L60.4)
- • Functional hair & scalp impact requiring minoxidil growth-phase extension [Hair Problems L60.4] evaluation (L60.4)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hair Problems Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L60.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Hair Loss, Alopecia & Scalp Conditions | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Ferritin [Hair Problems L60.4] | 70 – 150 ng/mL (L60.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Hair Problems (L60.4: T4) | TSH 0.8 – 2.5 mIU/L (L60.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Hair Problems (L60.4: & Zinc) | 25(OH)D 45 – 70 ng/mL (L60.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hair Problems
Treatment selection for Hair Problems depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hair Problems)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Interventions for female pattern hair: What a 2,349-Participant Study Found Further direct comparison studies of minoxidil 5% applied once a day, which could improve staying on track with medication when compared to minoxidil 2% twice daily, are still required. The Cochrane database of systematic reviews • 2012-05-16 • Meta-Analysis | N = 2,349 | 99/100 | PMID 22592723 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Clinical trial of 5% skin-applied minoxidil versus 2% skin-applied minoxidil and: What a 393-Participant Study Found In men with AGA, 5% applied to the skin minoxidil was clearly superior to 2% applied to the skin minoxidil and placebo in increasing hair regrowth, and the magnitude of its effect was marked (45% more hair regrowth than 2%... Journal of the American Academy of Dermatology • 2002-09-15 • Randomized Controlled Trial | N = 393 | 93/100 | PMID 12196747 ↗ |
| New Insights on A randomized, compared against a dummy pill (placebo) trial of 5% and 2%: What a 381-Participant Study Found In this 48-week study of 381 women with female pattern hair loss, 5% applied to the skin minoxidil was superior to placebo on each of the 3 primary efficacy end points: promoting hair growth as measured by change in nonvellus... Journal of the American Academy of Dermatology • 2004-04-15 • Randomized Controlled Trial | N = 381 | 93/100 | PMID 15034503 ↗ |
| New Insights on Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in: What a 718-Participant Study Found Patients receiving active ritlecitinib doses reported favorable results versus placebo in satisfaction with hair growth up to week 48. Dermatology (Basel, Switzerland) • 2024-01-15 • Phase III Randomized Trial | N = 718 | 93/100 | PMID 38934147 ↗ |
Hair Problems Patient Community & “People Like Me” Threads
Filter Hair Problems community threads and patient logs by age, biological sex, dosage, and treatment duration.